AKRO Akero Therapeutics Inc

Price (delayed)

$37.45

Market cap

$1.76B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.87

Enterprise value

$1.52B

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, ...

Highlights
Akero Therapeutics's quick ratio has surged by 146% YoY and by 24% QoQ
Akero Therapeutics's EPS has increased by 15% QoQ
AKRO's equity has surged by 93% year-on-year but it is down by 4.9% since the previous quarter
AKRO's net income is down by 11% YoY but it is up by 8% QoQ

Key stats

What are the main financial stats of AKRO
Market
Shares outstanding
46.97M
Market cap
$1.76B
Enterprise value
$1.52B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$111.29M
EBITDA
-$111.03M
Free cash flow
-$92.52M
Per share
EPS
-$2.87
Free cash flow per share
-$2.37
Book value per share
$6.98
Revenue per share
$0
TBVPS
$9.15
Balance sheet
Total assets
$356.57M
Total liabilities
$30.01M
Debt
$10.62M
Equity
$326.56M
Working capital
$336.09M
Liquidity
Debt to equity
0.03
Current ratio
18.61
Quick ratio
18.42
Net debt/EBITDA
2.15
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-41.1%
Return on equity
-46.4%
Return on invested capital
-560.3%
Return on capital employed
-33%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKRO stock price

How has the Akero Therapeutics stock price performed over time
Intraday
-6%
1 week
-6.91%
1 month
-10.47%
1 year
140.06%
YTD
-31.66%
QTD
-31.66%

Financial performance

How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$115.16M
Net income
-$112.03M
Gross margin
N/A
Net margin
N/A
Akero Therapeutics's operating income has decreased by 14% YoY but it has increased by 6% from the previous quarter
AKRO's net income is down by 11% YoY but it is up by 8% QoQ

Growth

What is Akero Therapeutics's growth rate over time

Valuation

What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
5.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has increased by 15% QoQ
AKRO's equity has surged by 93% year-on-year but it is down by 4.9% since the previous quarter
The stock's P/B is 25% above its last 4 quarters average of 4.3

Efficiency

How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on invested capital has shrunk by 156% YoY but it has surged by 97% QoQ
Akero Therapeutics's return on equity has increased by 23% QoQ and by 3.9% YoY
The ROA has grown by 21% from the previous quarter and by 7% YoY

Dividends

What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKRO.

Financial health

How did Akero Therapeutics financials performed over time
Akero Therapeutics's quick ratio has surged by 146% YoY and by 24% QoQ
The current ratio has soared by 142% year-on-year and by 24% since the previous quarter
AKRO's debt is 97% smaller than its equity
The debt to equity has soared by 200% YoY
AKRO's equity has surged by 93% year-on-year but it is down by 4.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.